Ign-Es001
Chronic Widespread Pain
IgNova GmbHN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
101 Active assets in the Chronic Widespread Pain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(±)-TRAMADOL EMS | Phase 4 | BBB |
METHADONE Cari Health Inc. | Phase 4 | BBB |
LIDOCAINE National and Kapodistrian University of Athens | Phase 4 | BBB |
NEPENTHE Bursa City Hospital | Phase 4 | BBB |
FENTANYL Aga Khan University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Ign-Es001 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →